Oral azole antifungal prophylaxis in Japanese patients with chronic lymphocytic leukemia receiving ibrutinib: a nationwide cohort study

Leuk Lymphoma. 2023 Mar;64(3):730-733. doi: 10.1080/10428194.2022.2161305. Epub 2022 Dec 28.

Authors

Takeo Yasu¹, Kotono Sakurai¹, Makoto Hoshino¹, Manabu Akazawa²

Affiliations

¹ Department of Medicinal Therapy Research, Pharmaceutical Education and Research Center, Meiji Pharmaceutical University, Noshio, Tokyo, Japan.
² Department of Public Health and Epidemiology, Meiji Pharmaceutical University, Noshio, Tokyo, Japan.

PMID: 36576099
DOI: 10.1080/10428194.2022.2161305

No abstract available

MeSH terms

Antifungal Agents* / therapeutic use
Azoles / therapeutic use
Cohort Studies
East Asian People
Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / complications
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Protein Kinase Inhibitors / therapeutic use

Substances

Antifungal Agents
Azoles
ibrutinib
Protein Kinase Inhibitors